Marjan Boerma
Concepts (475)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart | 30 | 2023 | 357 | 8.230 |
Why?
| | Radiation Injuries | 17 | 2024 | 110 | 3.620 |
Why?
| | Radiation Injuries, Experimental | 15 | 2016 | 81 | 3.420 |
Why?
| | Oxygen | 12 | 2023 | 336 | 2.900 |
Why?
| | Heart Diseases | 10 | 2024 | 222 | 2.800 |
Why?
| | Protons | 5 | 2023 | 71 | 2.640 |
Why?
| | Cosmic Radiation | 9 | 2025 | 38 | 2.490 |
Why?
| | Radiation-Protective Agents | 14 | 2021 | 72 | 2.380 |
Why?
| | Myocardium | 15 | 2021 | 480 | 2.350 |
Why?
| | Animals | 94 | 2025 | 13523 | 2.110 |
Why?
| | Tocotrienols | 7 | 2019 | 37 | 1.770 |
Why?
| | Rats | 33 | 2023 | 3202 | 1.700 |
Why?
| | Space Flight | 7 | 2021 | 32 | 1.620 |
Why?
| | Mitochondria, Heart | 4 | 2018 | 40 | 1.530 |
Why?
| | Oxidative Stress | 16 | 2024 | 810 | 1.520 |
Why?
| | Mice, Inbred C57BL | 29 | 2025 | 1903 | 1.420 |
Why?
| | Radiation, Ionizing | 9 | 2021 | 101 | 1.280 |
Why?
| | Mice | 46 | 2025 | 5965 | 1.260 |
Why?
| | Intestine, Small | 5 | 2021 | 115 | 1.240 |
Why?
| | Mast Cells | 8 | 2014 | 55 | 1.230 |
Why?
| | Pyrroles | 4 | 2016 | 71 | 1.050 |
Why?
| | Rats, Sprague-Dawley | 18 | 2020 | 1552 | 1.020 |
Why?
| | Male | 58 | 2025 | 26696 | 0.990 |
Why?
| | DNA Methylation | 5 | 2025 | 592 | 0.950 |
Why?
| | Protein C | 3 | 2023 | 20 | 0.950 |
Why?
| | Weightlessness Simulation | 3 | 2025 | 22 | 0.950 |
Why?
| | Intestines | 7 | 2021 | 154 | 0.940 |
Why?
| | Gamma Rays | 4 | 2020 | 49 | 0.940 |
Why?
| | Radiation Protection | 3 | 2021 | 47 | 0.930 |
Why?
| | Hippocampus | 7 | 2021 | 201 | 0.900 |
Why?
| | Dose-Response Relationship, Radiation | 14 | 2023 | 183 | 0.810 |
Why?
| | Cone-Beam Computed Tomography | 2 | 2022 | 34 | 0.780 |
Why?
| | Astronauts | 2 | 2024 | 5 | 0.760 |
Why?
| | Oxygen Radioisotopes | 2 | 2019 | 14 | 0.760 |
Why?
| | Biology | 1 | 2021 | 8 | 0.750 |
Why?
| | Endothelial Cells | 8 | 2023 | 283 | 0.740 |
Why?
| | Radiation Tolerance | 3 | 2014 | 84 | 0.740 |
Why?
| | Radiobiology | 3 | 2021 | 21 | 0.730 |
Why?
| | Immunomodulation | 1 | 2021 | 37 | 0.730 |
Why?
| | Pentoxifylline | 2 | 2013 | 13 | 0.720 |
Why?
| | Skin | 4 | 2021 | 418 | 0.710 |
Why?
| | Environmental Pollution | 1 | 2021 | 14 | 0.700 |
Why?
| | Vitamin E | 6 | 2021 | 77 | 0.700 |
Why?
| | Aorta, Abdominal | 1 | 2020 | 39 | 0.660 |
Why?
| | Gene Expression Regulation | 7 | 2021 | 1006 | 0.660 |
Why?
| | Models, Animal | 8 | 2022 | 228 | 0.610 |
Why?
| | Ions | 4 | 2023 | 32 | 0.600 |
Why?
| | Receptor, Bradykinin B2 | 2 | 2015 | 7 | 0.580 |
Why?
| | Mitochondria | 4 | 2020 | 428 | 0.580 |
Why?
| | Heptanoic Acids | 3 | 2008 | 34 | 0.570 |
Why?
| | Glutathione Transferase | 2 | 2015 | 176 | 0.550 |
Why?
| | Radiotherapy, Image-Guided | 3 | 2016 | 25 | 0.550 |
Why?
| | Myocarditis | 2 | 2021 | 49 | 0.550 |
Why?
| | Radiation Dosage | 7 | 2021 | 162 | 0.550 |
Why?
| | Palladium | 1 | 2017 | 4 | 0.540 |
Why?
| | Thioctic Acid | 1 | 2017 | 3 | 0.540 |
Why?
| | Intestinal Mucosa | 9 | 2021 | 224 | 0.540 |
Why?
| | Humans | 44 | 2025 | 52336 | 0.540 |
Why?
| | Neoplasms | 5 | 2021 | 1305 | 0.540 |
Why?
| | Gene-Environment Interaction | 1 | 2017 | 40 | 0.540 |
Why?
| | Organometallic Compounds | 1 | 2017 | 43 | 0.530 |
Why?
| | Whole-Body Irradiation | 9 | 2021 | 127 | 0.520 |
Why?
| | Signal Transduction | 4 | 2024 | 1716 | 0.520 |
Why?
| | Leadership | 1 | 2017 | 104 | 0.510 |
Why?
| | Hematopoietic Stem Cells | 4 | 2017 | 188 | 0.460 |
Why?
| | Gene Deletion | 1 | 2015 | 276 | 0.440 |
Why?
| | Capsaicin | 1 | 2014 | 14 | 0.440 |
Why?
| | Sensory Receptor Cells | 1 | 2014 | 11 | 0.440 |
Why?
| | Neurons, Afferent | 1 | 2014 | 23 | 0.430 |
Why?
| | Disease Models, Animal | 7 | 2021 | 1484 | 0.430 |
Why?
| | Radiotherapy | 5 | 2015 | 129 | 0.420 |
Why?
| | Indoles | 1 | 2016 | 278 | 0.420 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 62 | 0.410 |
Why?
| | X-Rays | 4 | 2022 | 55 | 0.400 |
Why?
| | Kininogens | 1 | 2012 | 3 | 0.400 |
Why?
| | Kallikrein-Kinin System | 1 | 2012 | 3 | 0.400 |
Why?
| | Thoracic Neoplasms | 1 | 2012 | 13 | 0.390 |
Why?
| | Naphthalenes | 1 | 2013 | 121 | 0.390 |
Why?
| | Behavior, Animal | 5 | 2021 | 187 | 0.390 |
Why?
| | Pyridines | 1 | 2013 | 133 | 0.380 |
Why?
| | Cognition | 3 | 2019 | 331 | 0.370 |
Why?
| | Fibroblasts | 3 | 2015 | 359 | 0.360 |
Why?
| | Doxorubicin | 3 | 2025 | 239 | 0.360 |
Why?
| | Apoptosis | 9 | 2020 | 1127 | 0.360 |
Why?
| | Intestinal Diseases | 2 | 2007 | 26 | 0.350 |
Why?
| | Methionine | 4 | 2020 | 136 | 0.350 |
Why?
| | Chromans | 3 | 2021 | 35 | 0.340 |
Why?
| | Up-Regulation | 5 | 2016 | 462 | 0.340 |
Why?
| | Gene Expression | 7 | 2019 | 623 | 0.340 |
Why?
| | Epigenesis, Genetic | 4 | 2025 | 407 | 0.340 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2017 | 39 | 0.340 |
Why?
| | Endothelium, Vascular | 4 | 2010 | 261 | 0.330 |
Why?
| | NF-E2-Related Factor 2 | 3 | 2020 | 47 | 0.320 |
Why?
| | Isothiocyanates | 2 | 2020 | 20 | 0.310 |
Why?
| | Antigens, CD | 3 | 2017 | 219 | 0.310 |
Why?
| | Gene Expression Profiling | 5 | 2018 | 1110 | 0.310 |
Why?
| | rho-Associated Kinases | 1 | 2008 | 18 | 0.300 |
Why?
| | Receptor, Endothelin A | 1 | 2008 | 8 | 0.300 |
Why?
| | alpha-Tocopherol | 1 | 2008 | 9 | 0.300 |
Why?
| | Metabolomics | 3 | 2025 | 151 | 0.300 |
Why?
| | Female | 19 | 2025 | 28105 | 0.300 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 145 | 0.290 |
Why?
| | Dendritic Spines | 5 | 2019 | 22 | 0.290 |
Why?
| | Hydrogen | 2 | 2018 | 14 | 0.290 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 297 | 0.290 |
Why?
| | Interleukin-11 | 1 | 2007 | 7 | 0.280 |
Why?
| | Lung | 3 | 2025 | 502 | 0.280 |
Why?
| | Cardiovascular Diseases | 3 | 2024 | 486 | 0.280 |
Why?
| | Sulfonamides | 1 | 2008 | 133 | 0.270 |
Why?
| | Solar Activity | 2 | 2018 | 9 | 0.270 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2006 | 412 | 0.270 |
Why?
| | Dendrites | 2 | 2017 | 30 | 0.270 |
Why?
| | Sulfhydryl Compounds | 1 | 2006 | 17 | 0.260 |
Why?
| | Cells, Cultured | 7 | 2016 | 1589 | 0.260 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 230 | 0.260 |
Why?
| | Heart Rate | 3 | 2021 | 319 | 0.260 |
Why?
| | Coronary Circulation | 1 | 2006 | 57 | 0.250 |
Why?
| | Immunohistochemistry | 3 | 2021 | 985 | 0.250 |
Why?
| | Myocardial Contraction | 1 | 2006 | 112 | 0.250 |
Why?
| | Adenosine | 1 | 2006 | 72 | 0.240 |
Why?
| | Dietary Supplements | 2 | 2020 | 464 | 0.240 |
Why?
| | Collagen | 4 | 2021 | 212 | 0.240 |
Why?
| | Mice, Knockout | 4 | 2024 | 909 | 0.240 |
Why?
| | Myocytes, Cardiac | 2 | 2018 | 145 | 0.240 |
Why?
| | Homocysteine | 1 | 2006 | 126 | 0.240 |
Why?
| | Vasodilation | 1 | 2006 | 99 | 0.240 |
Why?
| | Mitochondrial Membrane Transport Proteins | 2 | 2016 | 18 | 0.240 |
Why?
| | Fibrosis | 4 | 2021 | 197 | 0.230 |
Why?
| | Neurons | 2 | 2018 | 418 | 0.230 |
Why?
| | Cell Respiration | 2 | 2015 | 41 | 0.230 |
Why?
| | Jejunum | 3 | 2021 | 55 | 0.230 |
Why?
| | Maze Learning | 2 | 2021 | 35 | 0.220 |
Why?
| | Histone Deacetylases | 1 | 2024 | 51 | 0.220 |
Why?
| | von Willebrand Factor | 1 | 2004 | 44 | 0.220 |
Why?
| | Biological Factors | 1 | 2023 | 12 | 0.210 |
Why?
| | DNA Damage | 4 | 2016 | 307 | 0.210 |
Why?
| | Blood Cells | 4 | 2021 | 37 | 0.210 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 140 | 0.210 |
Why?
| | Sex Characteristics | 1 | 2025 | 198 | 0.210 |
Why?
| | Sulfoxides | 2 | 2020 | 21 | 0.210 |
Why?
| | Life Style | 1 | 2024 | 145 | 0.210 |
Why?
| | Thrombomodulin | 3 | 2015 | 26 | 0.210 |
Why?
| | Bone Marrow Cells | 4 | 2017 | 190 | 0.210 |
Why?
| | Heart Atria | 1 | 2023 | 63 | 0.210 |
Why?
| | Heart Ventricles | 2 | 2017 | 268 | 0.200 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 49 | 0.200 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 50 | 0.200 |
Why?
| | Reproducibility of Results | 2 | 2023 | 1214 | 0.200 |
Why?
| | Heart Transplantation | 1 | 2007 | 366 | 0.200 |
Why?
| | Retina | 2 | 2024 | 63 | 0.200 |
Why?
| | Glucocorticoids | 1 | 2024 | 235 | 0.200 |
Why?
| | Weightlessness | 2 | 2020 | 13 | 0.190 |
Why?
| | Rabbits | 1 | 2023 | 374 | 0.190 |
Why?
| | Editorial Policies | 1 | 2021 | 12 | 0.190 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 2021 | 11 | 0.190 |
Why?
| | Capsid Proteins | 1 | 2021 | 24 | 0.190 |
Why?
| | Proteome | 2 | 2020 | 170 | 0.190 |
Why?
| | Lymphocytes | 1 | 2022 | 150 | 0.180 |
Why?
| | Muscle Proteins | 1 | 2024 | 347 | 0.180 |
Why?
| | Reoviridae Infections | 1 | 2021 | 21 | 0.180 |
Why?
| | Carrier Proteins | 2 | 2013 | 326 | 0.180 |
Why?
| | Duodenum | 1 | 2021 | 34 | 0.180 |
Why?
| | Inflammation | 4 | 2023 | 642 | 0.180 |
Why?
| | Phosphorylation | 2 | 2013 | 531 | 0.180 |
Why?
| | Ventricular Remodeling | 2 | 2016 | 65 | 0.180 |
Why?
| | Immunoblotting | 1 | 2021 | 119 | 0.180 |
Why?
| | Ileum | 1 | 2021 | 88 | 0.180 |
Why?
| | Metabolome | 2 | 2023 | 102 | 0.180 |
Why?
| | Cell Count | 2 | 2013 | 144 | 0.180 |
Why?
| | Gastrointestinal Tract | 2 | 2020 | 108 | 0.180 |
Why?
| | Carbon | 2 | 2019 | 55 | 0.170 |
Why?
| | Cytokines | 4 | 2018 | 625 | 0.170 |
Why?
| | Blood-Brain Barrier | 1 | 2020 | 49 | 0.170 |
Why?
| | Thymus Gland | 1 | 2020 | 42 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2021 | 140 | 0.170 |
Why?
| | Rats, Long-Evans | 1 | 2020 | 25 | 0.170 |
Why?
| | Time Factors | 5 | 2025 | 2957 | 0.170 |
Why?
| | Somatostatin | 2 | 2011 | 30 | 0.170 |
Why?
| | Abdomen | 1 | 2020 | 75 | 0.170 |
Why?
| | Research Design | 1 | 2022 | 354 | 0.160 |
Why?
| | Fluorouracil | 2 | 2017 | 59 | 0.160 |
Why?
| | Spleen | 1 | 2020 | 173 | 0.160 |
Why?
| | Genotype | 1 | 2021 | 569 | 0.160 |
Why?
| | Hematopoiesis | 2 | 2021 | 70 | 0.160 |
Why?
| | Linear Energy Transfer | 2 | 2017 | 14 | 0.160 |
Why?
| | Adaptation, Ocular | 1 | 2019 | 2 | 0.160 |
Why?
| | Blood-Retinal Barrier | 1 | 2019 | 6 | 0.160 |
Why?
| | Macrophages | 2 | 2014 | 378 | 0.150 |
Why?
| | Thrombosis | 1 | 2021 | 253 | 0.150 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 809 | 0.150 |
Why?
| | Gravity, Altered | 1 | 2018 | 3 | 0.150 |
Why?
| | Social Behavior | 1 | 2019 | 73 | 0.150 |
Why?
| | Wound Healing | 3 | 2009 | 219 | 0.150 |
Why?
| | Antioxidants | 2 | 2017 | 258 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 583 | 0.140 |
Why?
| | Environmental Exposure | 2 | 2024 | 216 | 0.140 |
Why?
| | Enzymes | 1 | 2017 | 29 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2017 | 36 | 0.140 |
Why?
| | Metagenome | 1 | 2017 | 39 | 0.140 |
Why?
| | Graft Survival | 2 | 2009 | 160 | 0.140 |
Why?
| | Memory, Short-Term | 1 | 2017 | 72 | 0.140 |
Why?
| | Staining and Labeling | 1 | 2017 | 92 | 0.130 |
Why?
| | Neuronal Plasticity | 1 | 2017 | 45 | 0.130 |
Why?
| | Diastole | 2 | 2008 | 67 | 0.130 |
Why?
| | Simvastatin | 2 | 2007 | 29 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 55 | 0.130 |
Why?
| | Administration, Oral | 2 | 2018 | 451 | 0.130 |
Why?
| | Stem Cells | 1 | 2017 | 182 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2007 | 139 | 0.130 |
Why?
| | Aging | 2 | 2023 | 708 | 0.130 |
Why?
| | Liver | 4 | 2018 | 1159 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 53 | 0.130 |
Why?
| | RNA, Messenger | 4 | 2020 | 1142 | 0.120 |
Why?
| | Heavy Ions | 1 | 2015 | 15 | 0.120 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2016 | 38 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.120 |
Why?
| | Obesity | 3 | 2019 | 1162 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 127 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2008 | 460 | 0.120 |
Why?
| | Cell Death | 1 | 2016 | 176 | 0.120 |
Why?
| | Embryo, Mammalian | 1 | 2015 | 71 | 0.120 |
Why?
| | Troponin I | 1 | 2015 | 19 | 0.120 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 230 | 0.120 |
Why?
| | Echocardiography | 2 | 2018 | 412 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 243 | 0.110 |
Why?
| | Infant | 1 | 2023 | 3684 | 0.110 |
Why?
| | Body Weight | 3 | 2021 | 522 | 0.110 |
Why?
| | MAP Kinase Signaling System | 2 | 2012 | 127 | 0.110 |
Why?
| | Carbon Tetrachloride | 1 | 2014 | 25 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2014 | 4 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2014 | 5 | 0.110 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 40 | 0.110 |
Why?
| | Denervation | 1 | 2014 | 19 | 0.110 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2014 | 23 | 0.110 |
Why?
| | Cardiac Output | 1 | 2014 | 41 | 0.110 |
Why?
| | bcl-2-Associated X Protein | 1 | 2014 | 58 | 0.110 |
Why?
| | Protein Kinase C-alpha | 1 | 2013 | 10 | 0.110 |
Why?
| | Protein Binding | 4 | 2021 | 680 | 0.110 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 113 | 0.110 |
Why?
| | Protein Conformation | 1 | 2014 | 179 | 0.110 |
Why?
| | Aldehydes | 1 | 2013 | 81 | 0.110 |
Why?
| | Organ Size | 1 | 2014 | 231 | 0.100 |
Why?
| | Cell Survival | 1 | 2015 | 602 | 0.100 |
Why?
| | Cardiovascular System | 1 | 2013 | 55 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 129 | 0.100 |
Why?
| | Drug Interactions | 1 | 2013 | 205 | 0.100 |
Why?
| | Organs at Risk | 1 | 2013 | 75 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 1377 | 0.100 |
Why?
| | Mitochondrial Swelling | 1 | 2012 | 4 | 0.100 |
Why?
| | Pancreas | 2 | 2011 | 71 | 0.100 |
Why?
| | Rats, Inbred BN | 1 | 2012 | 13 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2014 | 118 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 172 | 0.100 |
Why?
| | Radiation | 1 | 2012 | 14 | 0.100 |
Why?
| | Endothelin-1 | 1 | 2012 | 34 | 0.100 |
Why?
| | Mass Media | 1 | 2012 | 24 | 0.100 |
Why?
| | Brain | 1 | 2020 | 1323 | 0.100 |
Why?
| | Blood Cell Count | 3 | 2017 | 37 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1031 | 0.090 |
Why?
| | Research | 1 | 2012 | 106 | 0.090 |
Why?
| | Liver Cirrhosis | 1 | 2014 | 241 | 0.090 |
Why?
| | Blotting, Western | 1 | 2012 | 596 | 0.090 |
Why?
| | DNA | 2 | 2024 | 550 | 0.090 |
Why?
| | Cell Cycle | 2 | 2016 | 240 | 0.090 |
Why?
| | Receptor, PAR-2 | 1 | 2010 | 4 | 0.090 |
Why?
| | Cell Line | 2 | 2015 | 1045 | 0.090 |
Why?
| | Myeloid Cells | 2 | 2024 | 39 | 0.080 |
Why?
| | DNA Repair | 2 | 2016 | 195 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 138 | 0.080 |
Why?
| | Leukocytes | 1 | 2010 | 61 | 0.080 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 9 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 62 | 0.080 |
Why?
| | Random Allocation | 4 | 2010 | 287 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2010 | 117 | 0.080 |
Why?
| | Skin Transplantation | 1 | 2009 | 44 | 0.080 |
Why?
| | Collagen Type III | 1 | 2008 | 7 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2008 | 69 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2008 | 64 | 0.070 |
Why?
| | Receptors, AMPA | 2 | 2019 | 16 | 0.070 |
Why?
| | Cytoskeleton | 1 | 2008 | 39 | 0.070 |
Why?
| | Dentate Gyrus | 2 | 2019 | 19 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 186 | 0.070 |
Why?
| | Metabolic Networks and Pathways | 2 | 2019 | 93 | 0.070 |
Why?
| | Synapses | 2 | 2019 | 74 | 0.070 |
Why?
| | Transcription, Genetic | 2 | 2010 | 385 | 0.070 |
Why?
| | Collagen Type I | 1 | 2008 | 83 | 0.070 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2019 | 79 | 0.070 |
Why?
| | Hypolipidemic Agents | 1 | 2007 | 30 | 0.070 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 591 | 0.070 |
Why?
| | Transplantation, Heterotopic | 1 | 2007 | 7 | 0.070 |
Why?
| | Connective Tissue | 1 | 2006 | 10 | 0.070 |
Why?
| | Ileostomy | 1 | 2006 | 6 | 0.070 |
Why?
| | Tight Junctions | 2 | 2019 | 26 | 0.070 |
Why?
| | Orchiectomy | 1 | 2006 | 38 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2007 | 155 | 0.060 |
Why?
| | Mevalonic Acid | 1 | 2006 | 5 | 0.060 |
Why?
| | Atropine | 1 | 2006 | 30 | 0.060 |
Why?
| | Muscle Tonus | 1 | 2006 | 22 | 0.060 |
Why?
| | Theophylline | 1 | 2006 | 17 | 0.060 |
Why?
| | Nifedipine | 1 | 2006 | 25 | 0.060 |
Why?
| | Acetylcholine | 1 | 2006 | 55 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2006 | 75 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2007 | 491 | 0.060 |
Why?
| | Proteomics | 2 | 2019 | 326 | 0.060 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 60 | 0.060 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2006 | 81 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2006 | 93 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 429 | 0.060 |
Why?
| | Muscle Contraction | 1 | 2006 | 116 | 0.060 |
Why?
| | Tenascin | 1 | 2005 | 1 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2018 | 425 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2006 | 137 | 0.060 |
Why?
| | Genetic Techniques | 1 | 2005 | 15 | 0.060 |
Why?
| | Nucleic Acid Hybridization | 1 | 2005 | 57 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2005 | 50 | 0.060 |
Why?
| | SKP Cullin F-Box Protein Ligases | 1 | 2024 | 15 | 0.060 |
Why?
| | Receptors, Calcitriol | 1 | 2024 | 21 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 328 | 0.060 |
Why?
| | Calcitriol | 1 | 2024 | 39 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2005 | 137 | 0.060 |
Why?
| | Necrosis | 1 | 2005 | 173 | 0.060 |
Why?
| | Transcription Factors | 1 | 2008 | 574 | 0.060 |
Why?
| | Pressure | 1 | 2005 | 103 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 78 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2005 | 95 | 0.060 |
Why?
| | Phagocytosis | 1 | 2024 | 51 | 0.060 |
Why?
| | Amifostine | 1 | 2004 | 2 | 0.060 |
Why?
| | Endocardium | 1 | 2004 | 7 | 0.060 |
Why?
| | Endomyocardial Fibrosis | 1 | 2004 | 3 | 0.060 |
Why?
| | Radiometry | 2 | 2016 | 127 | 0.050 |
Why?
| | Premedication | 1 | 2004 | 18 | 0.050 |
Why?
| | Muscular Diseases | 1 | 2024 | 63 | 0.050 |
Why?
| | Ventricular Function, Left | 1 | 2005 | 172 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2024 | 30 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2024 | 72 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2024 | 141 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 347 | 0.050 |
Why?
| | Histones | 2 | 2017 | 316 | 0.050 |
Why?
| | Retinal Diseases | 1 | 2024 | 56 | 0.050 |
Why?
| | Extracellular Matrix | 1 | 2004 | 112 | 0.050 |
Why?
| | Electrocardiography | 1 | 2005 | 267 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2023 | 50 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2017 | 207 | 0.050 |
Why?
| | Radiotherapy Dosage | 2 | 2016 | 255 | 0.050 |
Why?
| | Ultracentrifugation | 1 | 2022 | 10 | 0.050 |
Why?
| | Chemokines | 2 | 2014 | 79 | 0.050 |
Why?
| | Cytogenetic Analysis | 1 | 2022 | 80 | 0.050 |
Why?
| | Biological Availability | 2 | 2013 | 108 | 0.050 |
Why?
| | Coronary Vessels | 1 | 2004 | 169 | 0.050 |
Why?
| | Peroxynitrous Acid | 2 | 2013 | 33 | 0.050 |
Why?
| | Breast Neoplasms | 3 | 2018 | 1206 | 0.050 |
Why?
| | Interleukin-12 | 2 | 2014 | 27 | 0.050 |
Why?
| | Orthoreovirus, Mammalian | 1 | 2021 | 17 | 0.050 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2021 | 51 | 0.050 |
Why?
| | Primates | 1 | 2021 | 22 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 80 | 0.050 |
Why?
| | NF-kappa B | 1 | 2023 | 328 | 0.050 |
Why?
| | Macaca mulatta | 1 | 2021 | 92 | 0.050 |
Why?
| | Citrulline | 2 | 2014 | 104 | 0.050 |
Why?
| | Virulence | 1 | 2021 | 167 | 0.040 |
Why?
| | Organ Specificity | 1 | 2021 | 117 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2022 | 293 | 0.040 |
Why?
| | Catecholamines | 1 | 2020 | 44 | 0.040 |
Why?
| | Drinking | 1 | 2020 | 43 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2021 | 366 | 0.040 |
Why?
| | Occupational Exposure | 2 | 2013 | 111 | 0.040 |
Why?
| | Virus Replication | 1 | 2021 | 150 | 0.040 |
Why?
| | Biological Transport | 1 | 2020 | 158 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2021 | 188 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 46 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 173 | 0.040 |
Why?
| | Swine | 1 | 2021 | 426 | 0.040 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2019 | 7 | 0.040 |
Why?
| | DNA, Satellite | 1 | 2019 | 13 | 0.040 |
Why?
| | Centromere | 1 | 2019 | 13 | 0.040 |
Why?
| | Aquaporin 4 | 1 | 2019 | 8 | 0.040 |
Why?
| | Sarcopenia | 1 | 2020 | 98 | 0.040 |
Why?
| | Crystallins | 1 | 2019 | 11 | 0.040 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2019 | 29 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2020 | 186 | 0.040 |
Why?
| | Eye Proteins | 1 | 2019 | 16 | 0.040 |
Why?
| | Risk Factors | 2 | 2024 | 3872 | 0.040 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2019 | 90 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 7 | 0.040 |
Why?
| | Intraocular Pressure | 1 | 2019 | 59 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2019 | 232 | 0.040 |
Why?
| | Protein Subunits | 1 | 2019 | 80 | 0.040 |
Why?
| | Retinal Pigment Epithelium | 1 | 2018 | 14 | 0.040 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 32 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2018 | 97 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 46 | 0.040 |
Why?
| | Drug Synergism | 1 | 2018 | 148 | 0.040 |
Why?
| | Transcriptome | 1 | 2020 | 367 | 0.040 |
Why?
| | Carbohydrate Metabolism | 1 | 2017 | 25 | 0.030 |
Why?
| | CA3 Region, Hippocampal | 1 | 2017 | 4 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 222 | 0.030 |
Why?
| | CA1 Region, Hippocampal | 1 | 2017 | 19 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 338 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2018 | 122 | 0.030 |
Why?
| | Methylation | 1 | 2017 | 126 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 671 | 0.030 |
Why?
| | Models, Genetic | 1 | 2017 | 172 | 0.030 |
Why?
| | Silver Staining | 1 | 2016 | 8 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2019 | 273 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 192 | 0.030 |
Why?
| | Arkansas | 1 | 2022 | 2028 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2016 | 43 | 0.030 |
Why?
| | Blood Glucose | 1 | 2019 | 471 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 404 | 0.030 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2016 | 70 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 102 | 0.030 |
Why?
| | Endothelium | 1 | 2015 | 38 | 0.030 |
Why?
| | Hydroxy Acids | 1 | 2014 | 8 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2014 | 39 | 0.030 |
Why?
| | NF-E2 Transcription Factor, p45 Subunit | 1 | 2013 | 3 | 0.030 |
Why?
| | Permeability | 1 | 2014 | 67 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 38 | 0.030 |
Why?
| | Mitosis | 1 | 2014 | 89 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 88 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 1436 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2014 | 84 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 44 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 122 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 13 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2013 | 194 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 73 | 0.030 |
Why?
| | Gene Targeting | 1 | 2013 | 30 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 88 | 0.030 |
Why?
| | Drug Design | 1 | 2013 | 121 | 0.030 |
Why?
| | Binding Sites | 1 | 2013 | 379 | 0.030 |
Why?
| | Models, Molecular | 1 | 2013 | 352 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 306 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 563 | 0.020 |
Why?
| | Trypsin | 1 | 2011 | 11 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2012 | 274 | 0.020 |
Why?
| | GTP Cyclohydrolase | 1 | 2010 | 4 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 23 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 64 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2011 | 179 | 0.020 |
Why?
| | Radioactive Fallout | 1 | 2010 | 3 | 0.020 |
Why?
| | Deferoxamine | 1 | 2009 | 9 | 0.020 |
Why?
| | Pericarditis | 1 | 2010 | 20 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 743 | 0.020 |
Why?
| | Oligopeptides | 1 | 2010 | 93 | 0.020 |
Why?
| | Hodgkin Disease | 1 | 2010 | 49 | 0.020 |
Why?
| | Cesium Radioisotopes | 1 | 2009 | 3 | 0.020 |
Why?
| | Thermoluminescent Dosimetry | 1 | 2009 | 7 | 0.020 |
Why?
| | Chemokine CXCL9 | 1 | 2009 | 9 | 0.020 |
Why?
| | Bacterial Translocation | 1 | 2009 | 15 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 134 | 0.020 |
Why?
| | Forecasting | 1 | 2010 | 154 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 93 | 0.020 |
Why?
| | Mutation | 1 | 2015 | 1351 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2009 | 86 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 7 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2008 | 20 | 0.020 |
Why?
| | 14-3-3 Proteins | 1 | 2008 | 18 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 288 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 86 | 0.020 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 37 | 0.020 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2008 | 56 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2009 | 244 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 484 | 0.020 |
Why?
| | Receptors, Thrombin | 1 | 2007 | 13 | 0.020 |
Why?
| | Thrombin | 1 | 2007 | 38 | 0.020 |
Why?
| | Survival Rate | 1 | 2010 | 940 | 0.020 |
Why?
| | Tissue Plasminogen Activator | 1 | 2008 | 109 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2009 | 5407 | 0.020 |
Why?
| | Abdominal Neoplasms | 1 | 2007 | 16 | 0.020 |
Why?
| | Pelvic Neoplasms | 1 | 2007 | 13 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2007 | 143 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2010 | 297 | 0.020 |
Why?
| | Incidence | 1 | 2007 | 1059 | 0.010 |
Why?
| | Quality of Life | 1 | 2007 | 868 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2006 | 1066 | 0.010 |
Why?
|
|
Boerma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|